In February 2026, Zelira Therapeutics announced the completion of a $32.98 million financing (approximately 230 million RMB) through its HOPE®1 special purpose vehicle (SPV), led by the TGC Biotechnology Fund under ThirdGate Capital. After this financing, the cumulative funds raised by the SPV reached $36.56 million.

Zelira Therapeutics is a world-leading biopharmaceutical company headquartered in Perth, Australia. It specializes in the research, development, production, and commercialization of cannabinoid-based drugs. Its new drug research and development layout is centered on "clinical validation + technological innovation + global implementation", focusing on unmet medical needs such as neuropsychiatric diseases, sleep disorders, neuropathy, and skin diseases. Leveraging its proprietary Zyraydi™ encapsulation technology to enhance the solubility, stability, and delivery efficiency of oral formulations, Zelira adopts an innovative commercialization model of "launch first, learn later, and optimize afterward". Meanwhile, it accelerates the drug launch process through the FDA 505(b)(2) regulatory pathway. Its business covers key markets such as Australia, the United States, and Europe, and it is committed to building a global integrated research, development, and commercialization platform for cannabinoid-based drugs.

The company's core management team has extensive experience in the pharmaceutical industry. It is led by global managing director & CEO Dr. Oludare Odumosu. Core members include VP of Commercial & Partnering Greg Blake, VP of Finance And Accounting Rahul Ganesan, etc. Meanwhile, it has a professional team for clinical research and technological R&D, covering multiple fields such as cannabinoid drug research and development, clinical trials, and commercial promotion. In addition, Osagie Imasogie concurrently serves as the executive chairman of HOPE®1 Special Purpose Vehicle (SPV), providing all-round support for the advancement of the company's pipeline and strategic layout. In terms of new drug pipelines, Zelira Therapeutics has built a diversified pipeline of cannabinoid drugs and related derivative products. The core pipeline includes HOPE®1 for Autism Spectrum Disorder (with priority focus on Phelan-McDermid syndrome). This drug is prepared into pharmaceutical-grade oral capsules using Zyraydi™ technology, has accumulated a large amount of real-world data, and is advancing Phase II proof-of-concept trials. It is planned to submit an NDA application in 2027.

In addition, there is ZeniVol® for chronic insomnia (Phase Ⅰb/Ⅱa clinical trials completed, confirming its safety and efficacy), ZLT-L-007 for diabetic neuropathy (performed better than Lyrica® in IRB-approved studies, and Phase Ⅱ clinical trials are being prepared). At the same time, it has laid out oral care products such as Sprinjene and dermatological treatment products like RavFive™, forming a complete pipeline matrix covering clinical-stage drugs and commercialized products, which takes both R&D innovation and market practicality into account.